<DOC>
	<DOC>NCT00517920</DOC>
	<brief_summary>Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)</brief_summary>
	<brief_title>Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)</brief_title>
	<detailed_description>An Open-label, Phase 2 study of efficacy and tolerability of ABT-869 in advanced hepatocellular carcinoma (HCC)</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>Inclusion Criteria Subject must be greater than or equal to 18 years of age Subject must be diagnosed with unresectable or metastatic HCC Subjects must have a measurable lesion by RECIST on CT scan in at least one site which has not received radiation Subject has an Eastern Cooperative Oncology Group (ECOG) Performance status of 02 No other active malignancy within the past 5 years Exclusion Criteria Subject has received targeted VEGF/PDGF/TKI therapy. Prior Avastin is allowed Subject has ChildPugh grade Class C hepatic impairment The subject has proteinuria Common Toxicity Criteria (CTC) grade &gt; 1 as measured by routine urinalysis or 24 hour urine collection during screening assessment Subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure &gt; 100 mmHg or systolic blood pressure &gt; 150 mmHg. Subjects may be rescreened if blood pressure is shown to be controlled with or without intervention The subject has a documented left ventricular Ejection Fraction &lt; 50% Subject is receiving therapeutic anticoagulation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>